4.7 Article

Intravital Multiphoton Imaging of Cutaneous Immune Responses

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 134, Issue 11, Pages 2680-2684

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/jid.2014.225

Keywords

-

Categories

Ask authors/readers for more resources

Varieties of immune cells orchestrate cutaneous immune responses. To capture such dynamic phenomena, intravital imaging is an important technique and it may provide substantial information that is not available using the conventional histological analysis. Multiphoton microscopy enables the direct, three-dimensional, and minimally invasive imaging of biological samples with high spatio-temporal resolution, and it has now become the leading method for in vivo imaging studies. Using fluorescent dyes and transgenic reporter animals, not only skin structures but also cell- and humor-mediated cutaneous immune responses have been visualized.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Dermatology

The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry

Annelie H. Musters, Conor Broderick, David Prieto-Merino, Andrea Chiricozzi, Giovanni Damiani, Ketty Peris, Sandipan Dhar, Abhishek De, Esther Freeman, Bernd W. M. Arents, Tim Burton, Angela Leigh-Ann L. Bosma, Ching-Chi Chi, Godfrey Fletcher, Aaron M. Drucker, Kenji Kabashima, Emilie F. de Monchy, Maitreyee Panda, Dmitri Robert Wall, Christian Vestergaard, Emmanuel Mahe, Laura Bonzano, Leila Kattach, Maddalena Napolitano, Maria Fernanda Ordonez-Rubiano, Eva Haufe, Cataldo Patruno, Alan D. Irvine, Phyllis Spuls, Carsten Flohr

Summary: Limited data suggest that patients with atopic dermatitis (AD) receiving systemic immunomodulatory treatments have a lower risk of severe COVID-19 complications. Monotherapy with dupilumab is associated with lower hospitalization rates compared to other therapies. However, combination systemic treatments, particularly those including systemic corticosteroids, have the highest risk of severe COVID-19.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Letter Dermatology

Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis

Toshiaki Kogame, Satoru Yonekura, Paola Lovato, Masahiro Hirata, Riko Takimoto-ito, Tomoya Takegami, Takayoshi Komatsu-Fujii, Naotomo Kambe, Takashi Nomura, Mads A. Ropke, Kenji Kabashima

Summary: Despite the limited sample size and low frequency of skin ILCs in this study, the data suggest that ICOS+ ILCs express IL-13Ra1 and that the density of ICOS+ ILCs decreases after four weeks of tralokinumab treatment.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

Increased type I interferon expression from T cells in lesional skin of Degos disease

Yuki Honda Keith, Atsushi Otsuka, Toshiaki Kogame, Hiroyuki Ito, Shunya Usui, Masakazu Fujimoto, Keita Jinnouchi, Masahiro Hirata, Kazumitsu Sugiura, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Letter Dermatology

A case of Kimura disease with atopic dermatitis successfully treated with baricitinib

Marina Ueda, Toshiaki Kogame, Gyohei Egawa, Naotomo Kambe, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis

Hidehisa Saeki, Masashi Akiyama, Masatoshi Abe, Atsuyuki Igarashi, Shinichi Imafuku, Yukihiro Ohya, Norito Katoh, Hideto Kameda, Kenji Kabashima, Yuichiro Tsunemi, Michihiro Hide, Mamitaro Ohtsuki

Summary: This guidance provides information on the use of oral JAK inhibitors for the treatment of atopic dermatitis. It explains the role of oral JAK inhibitors in inhibiting the signal transduction of cytokines involved in the pathogenesis of atopic dermatitis. It also highlights the authorized oral JAK inhibitors for atopic dermatitis in Japan and emphasizes the importance of considering disease factors, treatment factors, and patient backgrounds in the selection of treatment options.

JOURNAL OF DERMATOLOGY (2023)

Review Dermatology

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events

R. Bissonnette, L. F. Eichenfield, E. Simpson, D. Thaci, K. Kabashima, J. P. Thyssen, E. Guttman-Yassky, F. P. Nunes, M. Gamalo, F. Ahmad, M. Kuligowski, K. Sun, C. Pipper, A. W. Christensen, P. D'Angelo, M. Milutinovic, A. Guettner, J. I. Silverberg

Summary: Despite the lack of guidelines for analyzing clinical trial data in atopic dermatitis (AD), using the estimand framework can help standardize the analysis and incorporate intercurrent events. Intercurrent events, such as rescue therapy and sleep deprivation, frequently occur in AD trials and their inconsistent handling limits result interpretation. Applying the estimand framework, as guided by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), can improve AD trial design and analysis by providing more reflective and informative results for clinicians to make treatment selection.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Medicine, General & Internal

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

Emma Guttman-Yassky, Eric L. Simpson, Kristian Reich, Kenji Kabashima, Ken Igawa, Tetsuya Suzuki, Hirotaka Mano, Takeshi Matsui, Ehsanollah Esfandiari, Masutaka Furue

Summary: This study evaluated the efficacy and safety of the anti-OX40 antibody rocatinlimab in patients with moderate-to-severe atopic dermatitis. The results showed significant reductions in EASI score at week 16 in patients receiving rocatinlimab compared to placebo. The treatment led to progressive improvements in atopic dermatitis, which were maintained in most patients after treatment discontinuation, and it was well tolerated.

LANCET (2023)

Article Allergy

Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan

Riko Takimoto-Ito, Naotomo Kambe, Toshiaki Kogame, Takashi Nomura, Kazushi Izawa, Tomoyasu Jo, Yasuhiro Kazuma, Hajime Yoshifuji, Yuya Tabuchi, Hiroyasu Abe, Mayuko Yamamoto, Kimiko Nakajima, Ozumi Tomita, Yosuke Yagi, Kazumoto Katagiri, Yuki Matsuzaka, Yohei Takeuchi, Miho Hatanaka, Takuro Kanekura, Sora Takeuchi, Takafumi Kadono, Yuya Fujita, Kiyoshi Migita, Takahiro Fujino, Takahiko Akagi, Tomoyuki Mukai, Tohru Nagano, Mitsuhiro Kawano, Hayato Kimura, Yukari Okubo, Akimichi Morita, Michihiro Hide, Takahiro Satoh, Akihiko Asahina, Nobuo Kanazawa, Kenji Kabashima

Summary: Schnitzler syndrome is a rare disorder characterized by chronic urticaria. A nationwide survey was conducted in Japan to determine the current status of the disease. Clinical information of 36 diagnosed cases was collected, providing insights into the clinical features and treatment of the syndrome. Continuous collection and long-term follow-up of clinical information are crucial for the appropriate management and further understanding of Schnitzler syndrome.

ALLERGOLOGY INTERNATIONAL (2023)

Review Immunology

Mast cells in type 2 skin inflammation: Maintenance and function

Yuki Honda Keith, Gyohei Egawa, Tetsuya Honda, Kenji Kabashima

Summary: Mast cells (MCs) are immune cells that play important roles in maintaining homeostasis and inflammatory states in tissues. They are involved in the pathogenesis of type 2 skin inflammation in atopic dermatitis (AD) through both pro- and anti-inflammatory effects. The activation of skin MCs by environmental factors like Staphylococcus aureus can lead to AD inflammation, while MCs also contribute to pruritus through IgE-dependent and -independent degranulation. On the other hand, MCs can suppress type 2 skin inflammation by promoting Treg expansion and enhancing skin barrier function.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Review Immunology

Exploring the roles of prostanoids, leukotriens, and dietary fatty acids in cutaneous inflammatory diseases: Insights from pharmacological and genetic approaches

Tetsuya Honda, Kenji Kabashima, Jun Kunisawa

Summary: Lipid mediators act through specific receptors on cell surfaces and play physiological roles locally at their production sites. Recent research has shed light on the roles of these mediators in various diseases, including inflammatory skin conditions. They not only signal themselves, but also enhance the signaling of other chemical mediators. Manipulating their signaling has the potential to be a novel therapeutic approach for human skin diseases.

IMMUNOLOGICAL REVIEWS (2023)

Article Dermatology

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

Kenji Kabashima, Takayo Matsumura, Yoshiteru Hayakawa, Makoto Kawashima

Summary: The background data from the Japanese phase 3 study showed that nemolizumab in combination with topical treatments can reduce pruritus in atopic dermatitis. This post-hoc analysis found that improvements in pruritus were associated with improvements in eczema symptoms, sleep quality, and daily life.

JOURNAL OF DERMATOLOGICAL TREATMENT (2023)

Letter Dermatology

A Japanese case of Vorner-type palmoplantar keratoderma caused by a novel KRT1 variant

Satoshi Nakamizo, Teruasa Murata, Yoshihiro Ishida, Satomi Aoki, Takashi Sasaki, Akiharu Kubo, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Article Pathology

Cutaneous arteritis with intimal fibrin ring and immature myeloid cell infiltrate: lymphocytic thrombophilic arteritis or histiocytoid polyarteritis nodosa?

Masakazu Fujimoto, Toshiya Miyake, Yo Kaku, Masahiro Hirata, Kenji Kabashima, Hironori Haga

Summary: This study aimed to resolve the ongoing debate on whether lymphocytic thrombophilic arteritis (LTA) is a separate disease or a type of polyarteritis nodosa (PAN). Immunohistochemistry analysis of skin biopsies from five LTA patients revealed that the majority of infiltrating cells were myelomonocytic cells rather than lymphocytes. Based on these findings, PAN was considered a more appropriate diagnosis for the five cases. Further investigation is needed to determine if histiocytoid PAN with immature myeloid cells is the same disease as conventional PAN with mature neutrophils.

VIRCHOWS ARCHIV (2023)

Letter Dermatology

Lymphedema-associated angiosarcoma uniquely localized on the left thigh and anterior abdominal wall secondary to central obesity and multiple surgeries

Yui Hirano-Lotman, Toshiaki Kogame, Yo Kaku, Takayoshi Komatsu-Fujii, Yuichiro Endo, Takashi Nomura, Kenji Kabashima

JOURNAL OF DERMATOLOGY (2023)

Article Dermatology

Neutrophilic epitheliotropism, proposed as an auto-inflammatory condition of neutrophilic urticarial dermatosis including Schnitzler syndrome, is also observed in Japanese cases

Hitomi Nakaizumi, Naotomo Kambe, Hiroyuki Irie, Yo Kaku, Masakazu Fujimoto, Hajime Yoshifuji, Yasuhiro Kazuma, Kazumoto Katagiri, Takuro Kanekura, Kenji Kabashima

Summary: Schnitzler syndrome (SchS) is a rare autoinflammatory disease characterized by bone pain, recurrent fever, and other symptoms. A key feature of the syndrome is the presence of a persistent urticarial-like rash. Histopathological data suggests that neutrophilic epitheliotropism, or the tendency of neutrophils to infiltrate and affect epithelial tissue, can be a useful marker for diagnosing SchS and differentiating it from conventional urticaria. Understanding this characteristic is crucial for early diagnosis and appropriate treatment.

JOURNAL OF DERMATOLOGY (2023)

No Data Available